-
Discovery of pyrano[3,4-b]indoles as potent and selective HCV NS5B polymerase inhibitors.
Gopalsamy A,
Lim K,
Ciszewski G,
Park K,
Ellingboe JW,
Bloom J,
Insaf S,
Upeslacis J,
Mansour TS,
Krishnamurthy G,
Damarla M,
Pyatski Y,
Ho D,
Howe AY,
Orlowski M,
Feld B,
O'Connell J.
Chemical and Screening Sciences and Infectious Diseases, Wyeth Research, Pearl River, New York 10965, USA. gopalsa@wyeth.com
A novel series of HCV NS5B RNA-dependent RNA polymerase inhibitors containing a pyrano[3,4-b]indole scaffold is described leading to the discovery of compound 16, a highly potent and selective inhibitor that is active in the replicon system.
PMID: 15588095 [PubMed - indexed for MEDLINE]
-
Cited by 6 PubMed Central articles
-
Synergy of a hepatitis C virus (HCV) NS4A antagonist in combination with HCV protease and polymerase inhibitors.
Wyles DL, Kaihara KA, Schooley RT.
Antimicrob Agents Chemother. 2008 May; 52(5):1862-4. Epub 2008 Mar 10.
[Antimicrob Agents Chemother. 2008]
-
Identification and characterization of coumestans as novel HCV NS5B polymerase inhibitors.
Kaushik-Basu N, Bopda-Waffo A, Talele TT, Basu A, Costa PR, da Silva AJ, Sarafianos SG, Noël F.
Nucleic Acids Res. 2008 Mar; 36(5):1482-96. Epub 2008 Jan 18.
[Nucleic Acids Res. 2008]
-
Binding-site identification and genotypic profiling of hepatitis C virus polymerase inhibitors.
Pauwels F, Mostmans W, Quirynen LM, van der Helm L, Boutton CW, Rueff AS, Cleiren E, Raboisson P, Surleraux D, Nyanguile O, et al.
J Virol. 2007 Jul; 81(13):6909-19. Epub 2007 Apr 25.
[J Virol. 2007]
- » See all...